NCT07773467Not yet recruiting
Systemic Immune-Inflammation Index and Platelet Parameters in Diabetic Kidney Disease
Systemic Immune Inflammation Index With Related Blood Ratios and Platelet Parameters in Patients With Type 2 Diabetes Mellitus and Nephropathy
Source: ClinicalTrials.gov · Last updated 19 Aug 2026
Brief summary (registry, in English)
Diabetic kidney disease (DKD) is a frequent microvascular complication in individuals with type 2 diabetes mellitus (T2DM) and a major cause of chronic kidney failure worldwide. Chronic low-grade inflammation and platelet activation contribute significantly to renal microvascular damage. The purpose of this observational study is to evaluate whether routine blood test markers, specifically the Systemic Immune-Inflammation Index (SII), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and platelet indices (such as mean platelet volume \[MPV\] and platelet distribution width \[PDW\]), can serve as simple, accessible, and cost-effective biomarkers for identifying the presence and progression of diabetic kidney disease. Participants will include adult patients with type 2 diabetes categorized according to their urinary albumin-to-creatinine ratio (normoalbuminuria, microalbuminuria, and macroalbuminuria) as well as healthy control subjects. Complete blood counts, derived inflammatory indices, and renal parameters will be measured to assess their diagnostic accuracy for DKD.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 120 (estimated)
- First submitted
- 15 Aug 2026
- Start date
- Sept 2026
- Primary completion date
- Sept 2027
- Lead sponsor
- Assiut University
- Diseases
- Chronic kidney disease, Type 2 diabetes
- NCT number
- NCT07773467
What you commit to
- Study type: Observational
- Planned participants: 120
- From Sept 2026 to the primary completion date, Sept 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of immunosuppressive therapy, systemic corticosteroids, or cytotoxic medications within the past 3 months prior to enrollment.
Other illness
- Type 1 diabetes mellitus.
- Acute infections or clinical signs of active inflammation at the time of sampling.
- Chronic inflammatory or autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus).
- Known or recently diagnosed malignancies.
- Chronic liver diseases, including cirrhosis or hepatitis.
- Nephrotic syndrome or other known non-diabetic kidney diseases.
Other
- Pregnancy.
- Significant cardiovascular complications.
Who the study is looking for
- Adults aged 18 to 80 years, both males and females.
- Confirmed clinical diagnosis and history of Type 2 Diabetes Mellitus (T2DM).
- Healthy control subjects matched for age and sex (for the control cohort).
Age in the registry: 18 years to 80 years · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.